Eliglustat 1 mg | 99.71%
TargetMol
Eliglustat is an oral inhibitor of glucosylceramide synthase which is used in the therapy of type 1 Gaucher disease.
More Information Supplier PageEliglustat
Search Results
Eliglustat 10 mg | 99.71%
TargetMol
Eliglustat is an oral inhibitor of glucosylceramide synthase which is used in the therapy of type 1 Gaucher disease.
More Information Supplier PageEliglustat
1-Deoxynojirimycin 50 mg | 99.82%
TargetMol
1-Deoxynojirimycin is a potent α-glucosidase inhibitor, suppressing postprandial blood glucose, thereby possibly preventing diabetes mellitus.
More Information Supplier Page1-Deoxynojirimycin
1-Deoxynojirimycin 5 mg | 99.82%
TargetMol
1-Deoxynojirimycin is a potent α-glucosidase inhibitor, suppressing postprandial blood glucose, thereby possibly preventing diabetes mellitus.
More Information Supplier Page1-Deoxynojirimycin
Bay 59-3074 10 mg | 98.00%
TargetMol
Bay 59-3074 is a CB1/CB2 receptor partial agonist (Ki: 48.3/45.5 nM). In rat models of chronic neuropathic and inflammatory pain, it displays anti-hyperalgesic and antiallodynic properties.
More Information Supplier PageBay 59-3074
Bay 59-3074 100 mg | 98.00%
TargetMol
Bay 59-3074 is a CB1/CB2 receptor partial agonist (Ki: 48.3/45.5 nM). In rat models of chronic neuropathic and inflammatory pain, it displays anti-hyperalgesic and antiallodynic properties.
More Information Supplier PageBay 59-3074
polygalaxanthone III 10 mg | 97.54%
TargetMol
Polygalaxanthone III can significantly inhibit chlorzoxazone 6-hydroxylation catalyzed by CYP2E1.
More Information Supplier Pagepolygalaxanthone III
SR9011 5 mg | 99.60%
TargetMol
SR9011 is a REV-ERB agonist (IC50: 790 nM, REV-ERBα; IC50: 560 nM, REV-ERBβ).
More Information Supplier PageSR9011
SR9011 2 mg | 99.60%
TargetMol
SR9011 is a REV-ERB agonist (IC50: 790 nM, REV-ERBα; IC50: 560 nM, REV-ERBβ).
More Information Supplier PageSR9011
SR9011 10 mg | 99.60%
TargetMol
SR9011 is a REV-ERB agonist (IC50: 790 nM, REV-ERBα; IC50: 560 nM, REV-ERBβ).
More Information Supplier PageSR9011